GlassScriptPhysician profile
Justin Brackenrich
NPI 1669852729
$1,598.67
in general payments reported to CMS, 2019-2025
24 companies · $131 in 2025
The $131 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $315 · 2020: $423 · 2021: $361 · 2022: $155 · 2023: $73.84 · 2024: $141 · 2025: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $346.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $345.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $209.01 | 2020-2021 | |
| Exact Sciences Corporation | $156.89 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $149.65 | 2019-2021 | |
| Glaxosmithkline, LLC. | $145.84 | 2019-2022 | |
| Pfizer INC. | $139.44 | 2019-2021 | |
| Novo Nordisk INC | $138.02 | 2019-2022 | |
| Abbott Laboratories | $135.66 | 2021-2025 | Freestyle Libre |
| Daiichi Sankyo INC. | $85.14 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.55 | 2021-2023 | Xifaxan, Trulance |
| Abbvie INC. | $47.91 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $43.89 | 2021 | |
| Janssen Pharmaceuticals, INC | $32.94 | 2020-2021 | |
| Medtronic, INC. | $30.40 | 2022 | |
| Genentech USA, INC. | $29.19 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $27.21 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $24.61 | 2020-2021 | |
| Allergan, INC. | $22.78 | 2019-2020 | |
| Dexcom, INC. | $21.20 | 2024 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $17.51 | 2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $17.00 | 2023 | Farxiga |
| Cranial Technologies, INC | $16.77 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.09 | 2021 | |
| Phadia US INC. | $13.80 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Brackenrich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.